Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:10:55.199Z.
Consensus retrieved: 2026-10-06T09:10:06.484Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:10:55.199Z.
Quote observation: 2026-10-06T15:10:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Forward PE Ratio (N/A) = Dated Quote Price ($6.23) / Consensus Forward EPS ($-1.67)
FORWARD PE RATIO
N/A
Aura Biosciences, Inc.
Market Cap
$644.40M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aura Biosciences, Inc. (AURA) | $644.40M | N/A |
| OmniAb, Inc. (OABI)vs › | $647.30M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $636.34M | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $629.03M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.04M | N/A |
| Helus Pharma Inc. (HELP)vs › | $674.55M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.40M | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $611.30M | N/A |
| Annexon, Inc. (ANNX)vs › | $687.32M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.01M | 2.98 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.23, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.67 | $-1.77 – $-1.55 | 3 | n/m |
| 2027-12-31 | $-1.52 | $-1.78 – $-1.26 | 3 | n/m |
| 2028-12-31 | $-1.20 | $-1.24 – $-1.15 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
